Fulcrum Therapeutics
FULC
155 hedge funds and large institutions have $291M invested in Fulcrum Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 72 increasing their positions, 35 reducing their positions, and 42 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 35
64% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $2.08M
11.62% more ownership
Funds ownership: 107.68% → 119.3% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 169 → 155 (-14)
31% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 42
47% less capital invested
Capital invested by funds: $550M → $291M (-$259M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$39.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$39.7M |
| 3 |
BlackRock
New York
|
+$20.9M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$14.8M |
| 5 |
Jane Street
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$46.4M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$40.3M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$24M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$18M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$17.5M |
FULC Hedge Fund Activity: Q2 2026 in Review
155 institutional investors reported a position in Fulcrum Therapeutics (FULC) for Q2 2026, worth a combined $291M — down 47% from $550M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of FULC and 29 opened new positions — a net loss of 13 holders — while 35 trimmed existing stakes and 72 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $39.8M. The largest seller was RA Capital Management, exiting entirely with an estimated $46.4M sold.
- 155 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2026, down from 169 in Q1 2026.
- Funds reported $291M of Fulcrum Therapeutics stock for Q2 2026, down 47% quarter-over-quarter.
- 29 funds opened new Fulcrum Therapeutics positions in Q2 2026 and 42 closed out, a net change of -13 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2026 was EcoR1 Capital, an estimated $39.8M added.
- The largest Fulcrum Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $46.4M sold.
Based on aggregated 13F filings for Q2 2026.